Eli Lilly announced it will acquire Ajax Therapeutics for up to $2.3 billion in cash, adding next-generation JAK biology for myeloproliferative neoplasms. The deal gives Lilly access to AJ1-11095, a Type II JAK2 inhibitor in Phase 1 testing for myelofibrosis, with a development pathway aimed at deeper and more durable disease control than incumbent Type I therapies. Lilly framed the acquisition as a pipeline expansion using its development and commercial capabilities in blood cancers. Ajax’s early program is being tested with the goal of addressing treatment discontinuation and loss of response observed with current JAK inhibitors in long-term patient management. The transaction also reinforces Lilly’s pattern of dealmaking to replenish pipeline depth in competitive hematology markets.